Back to top
more

Tonix Pharmaceuticals (TNXP)

(Delayed Data from NSDQ)

$0.16 USD

0.16
979,161

0.00 (2.04%)

Updated Apr 24, 2024 04:00 PM ET

After-Market: $0.16 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 42% (147 out of 252)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Balance Sheet

Fiscal Year End for Tonix Pharmaceuticals Holding Corp falls in the month of December.

All items in Millions except Per Share data.

12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Assets          
Cash & Equivalents 25 120 179 77 11
Receivables 0 0 0 0 0
Notes Receivable 0 0 0 0 0
Inventories 14 0 0 0 0
Other Current Assets 9 11 10 11 3
Total Current Assets 48 131 189 88 14
Net Property & Equipment 94 94 51 9 0
Investments & Advances 0 0 0 0 0
Other Non-Current Assets 0 0 0 0 0
Deferred Charges 0 0 0 0 0
Intangibles 11 0 0 0 0
Deposits & Other Assets 1 0 0 0 0
Total Assets 154 226 241 98 15
Liabilities & Shareholders Equity 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Notes Payable 0 0 0 0 0
Accounts Payable 4 8 13 5 3
Current Portion Long-Term Debt 2 0 0 0 0
Current Portion Capital Leases 0 0 0 0 0
Accrued Expenses 12 10 8 5 2
Income Taxes Payable 0 0 0 0 0
Other Current Liabilities 0 0 0 0 0
Total Current Liabilities 19 18 22 10 5
Mortgages 0 0 0 0 0
Deferred Taxes/Income 0 0 0 0 0
Convertible Debt 0 0 0 0 0
Long-Term Debt 7 0 0 0 0
Non-Current Capital Leases 0 0 0 0 0
Other Non-Current Liabilities 23 0 0 0 0
Minority Interest (Liabilities) 0 0 0 0 0
Total Liabilities 49 19 22 11 5
Shareholders Equity 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Preferred Stock 0 0 0 0 0
Common Stock (Par) 0 0 1 0 0
Capital Surplus 706 677 578 355 227
Retained Earnings -601 -470 -360 -268 -217
Other Equity 0 0 0 0 0
Treasury Stock 0 0 0 0 0
Total Shareholder's Equity 106 207 219 88 9
Total Liabilities & Shareholder's Equity 154 226 241 98 15
Total Common Equity 106 207 219 88 9
Shares Outstanding 58.60 9.20 2.40 1.30 0.00
Book Value Per Share 1.80 22.52 91.13 67.42 9.42

Fiscal Year End for Tonix Pharmaceuticals Holding Corp falls in the month of December.

All items in Millions except Per Share data.

3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Assets          
Cash & Equivalents -99,999 25 7 26 72
Receivables NA 0 2 0 0
Notes Receivable NA 0 0 0 0
Inventories NA 14 13 14 0
Other Current Assets NA 9 10 12 12
Total Current Assets NA 48 31 51 84
Net Property & Equipment NA 94 95 96 94
Investments & Advances NA 0 0 0 0
Other Non-Current Assets NA 0 0 0 0
Deferred Charges NA 0 0 0 0
Intangibles NA 11 11 11 0
Deposits & Other Assets NA 1 1 0 0
Total Assets NA 154 139 160 179
Liabilities & Shareholders Equity 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Notes Payable NA 0 0 0 0
Accounts Payable NA 4 8 8 8
Current Portion Long-Term Debt NA 2 0 0 0
Current Portion Capital Leases NA 0 0 0 0
Accrued Expenses NA 12 10 10 5
Income Taxes Payable NA 0 0 0 0
Other Current Liabilities NA 0 0 0 0
Total Current Liabilities NA 19 18 18 13
Mortgages NA 0 0 0 0
Deferred Taxes/Income NA 0 0 0 0
Convertible Debt NA 0 0 0 0
Long-Term Debt NA 7 0 0 0
Non-Current Capital Leases NA 0 0 0 0
Other Non-Current Liabilities NA 0 0 0
Minority Interest (Liabilities) NA 0 0 0 0
Total Liabilities NA 49 18 19 14
Shareholders Equity 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Preferred Stock NA 0 0 0 0
Common Stock (Par) NA 0 0 0 0
Capital Surplus NA 706 694 686 683
Retained Earnings NA -601 -573 -545 -517
Other Equity NA 0 0 0 0
Treasury Stock NA 0 0 0 0
Total Shareholder's Equity NA 106 121 140 165
Total Liabilities & Shareholder's Equity NA 154 139 160 179
Total Common Equity 0 106 121 140 165
Shares Outstanding 84.40 58.60 17.70 10.70 10.00
Book Value Per Share 0.00 1.80 6.83 13.13 16.54